Zinger Key Points
- A new Michigan bill seeks to legalize psychedelic mushrooms for PTSD treatment, allowing adults to possess up to two ounces.
- The bill focuses on personal use, and does not establish a legal framework for producing or distributing psychedelics.
- Markets are swinging wildly, but for Matt Maley, it's just another opportunity to trade. His clear, simple trade alerts have helped members lock in gains as high as 100% and 450%. Now, you can get his next trade signal—completely free.
Michigan could soon become the latest state to allow the legal use of psychedelic mushrooms for individuals with post traumatic stress disorder (PTSD). As Marijuana Moment reported, a new bill introduced by State Rep. Mike McFall (D) proposes legalizing up to two ounces of psilocybin mushrooms for personal use for people over 18 who have been diagnosed with post-traumatic stress disorder (PTSD). The bill, HB 5980, also extends to psilocin, another psychoactive compound found in mushrooms.
Key Details Of Bill: No Commercial Psychedelic Industry Proposed
The proposal focuses on protecting individuals with PTSD from prosecution for possessing psilocybin or psilocin for personal use and does not establish a legal framework for producing or distributing psychedelics. The bill states that qualified individuals would not be "in violation of" laws prohibiting the creation, manufacture, possession or use of psilocybin and psilocin. HB 5980 is awaiting a hearing in the House Criminal Justice Committee.
At the local level, several Michigan cities like Detroit, Ann Arbor and Ypsilanti, have already deprioritized the enforcement of laws against psychedelics. However, a state-level push for broader decriminalization has so far struggled to gain momentum. The proposed legislation comes as psychedelic therapy continues to gain mainstream attention, with emerging research suggesting psilocybin's potential to treat mental health disorders such as depression, anxiety and substance use disorders. Federal agencies, including the National Institutes of Health, have acknowledged the growing evidence of psilocybin's therapeutic benefits, though caution remains regarding its recreational use.
Cover image made with AI
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!